The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites.
P. Ruf
Employment or Leadership Position - TRION Pharma
M. J├Ąger
Employment or Leadership Position - TRION Pharma
B. Foerster
Employment or Leadership Position - TRION Pharma
H. Martinius
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
D. Seimetz
Employment or Leadership Position - Fresenius Biotech
Stock Ownership - Fresenius Biotech
H. Lindhofer
Employment or Leadership Position - TRION Pharma
Stock Ownership - TRION Pharma